Company: ZLAB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001704292-25-000024
Chunk: 41

Company: Zai Lab Ltd
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
 offering costs(854)— Employee taxes paid related to net share settlement of equity awards(8,218)— Net cash provided by financing activities72,783 112,077 Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash311 402 Net increase (decrease) in cash, cash equivalents and restricted cash267,489 (74,060)Cash, cash equivalents and restricted cash - beginning of period550,781 791,264 Cash, cash equivalents and restricted cash - end of period818,270 717,204 Supplemental disclosure on non-cash investing and financing activities  Payables for purchase of property and equipment468 2,612 Payables for acquisition of intangible assets1,158 11,358 Payables for public offering costs168 — Right-of-use asset acquired under operating leases— 3,945 Receivables for stock option exercise under equity incentive plans239 1,593 Supplemental disclosure of cash flow information  Cash paid for interest3,610 1,169 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

7

Zai Lab Limited Notes to the unaudited condensed consolidated financial statements 

1. Organization and Principal Activities 

Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. 

The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States. 

2. Basis of Presentation and Consolidation and Significant Accounting Policies 

(a) Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and